These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25712401)

  • 1. Quantitative motor assessment of dyskinesias in Parkinson's disease.
    Schaeffer E; Maetzler W; Liepelt-Scarfone I; Sass C; Reilmann R; Berg D
    J Neural Transm (Vienna); 2015 Sep; 122(9):1271-8. PubMed ID: 25712401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect.
    Ramsperger R; Meckler S; Heger T; van Uem J; Hucker S; Braatz U; Graessner H; Berg D; Manoli Y; Serrano JA; Ferreira JJ; Hobert MA; Maetzler W;
    Parkinsonism Relat Disord; 2016 May; 26():41-6. PubMed ID: 26952699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
    Gour J; Edwards R; Lemieux S; Ghassemi M; Jog M; Duval C
    Brain Res Bull; 2007 Sep; 74(1-3):66-74. PubMed ID: 17683791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
    Fabbrini G; Defazio G; Colosimo C; Suppa A; Bloise M; Berardelli A
    Mov Disord; 2009 Oct; 24(14):2091-6. PubMed ID: 19691126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
    Keijsers NL; Horstink MW; van Hilten JJ; Hoff JI; Gielen CC
    Mov Disord; 2000 Nov; 15(6):1104-11. PubMed ID: 11104192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
    Mera TO; Burack MA; Giuffrida JP
    Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():154-7. PubMed ID: 23365855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective measurement of dyskinesia in Parkinson's disease using a force plate.
    Chung KA; Lobb BM; Nutt JG; McNames J; Horak F
    Mov Disord; 2010 Apr; 25(5):602-8. PubMed ID: 20213818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
    Keijsers NL; Horstink MW; Gielen SC
    Mov Disord; 2003 Jan; 18(1):70-80. PubMed ID: 12518302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
    Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
    Fenney A; Jog MS; Duval C
    Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of spirography features for objective assessment of motor function in Parkinson's disease.
    Sadikov A; Groznik V; Možina M; Žabkar J; Nyholm D; Memedi M; Bratko I; Georgiev D
    Artif Intell Med; 2017 Sep; 81():54-62. PubMed ID: 28416144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.